Panagiotis A Konstantinopoulos1, Andrew J Wilson2, Jeanette Saskowski2, Erica Wass2, Dineo Khabele3. 1. Department of Medical Oncology, Medical Gynecologic Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 2. Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. Electronic address: dineo.khabele@vanderbilt.edu.
Abstract
OBJECTIVES: Approximately 50% of serous epithelial ovarian cancers (EOC) contain molecular defects in homologous recombination (HR) DNA repair pathways. Poly(ADP-ribose) polymerase inhibitors (PARPi) have efficacy in HR-deficient, but not in HR-proficient, EOC tumors as a single agent. Our goal was to determine whether the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), can sensitize HR-proficient ovarian cancer cells to the PARPi AZD-2281 (olaparib). METHODS: Ovarian cancer cell lines (SKOV-3, OVCAR-8, NCI/ADR-Res, UWB1.289 BRCA1null and UWB1.289+BRCA1 wild-type) were treated with saline vehicle, olaparib, SAHA or olaparib/SAHA. Sulforhodamine B (SRB) assessed cytotoxicity and immunofluorescence and Western blot assays assessed markers of apoptosis (cleaved PARP) and DNA damage (pH2AX and RAD51). Drug effects were also tested in SKOV-3 xenografts in Nude mice. Affymetrix microarray experiments were performed in vehicle and SAHA-treated SKOV-3 cells. RESULTS: In a microarray analysis, SAHA induced coordinated down-regulation of HR pathway genes, including RAD51 and BRCA1. Nuclear co-expression of RAD51 and pH2AX, a marker of efficient HR repair, was reduced approximately 40% by SAHA treatment alone and combined with olaparib. SAHA combined with olaparib induced apoptosis and pH2AX expression to a greater extent than either drug alone. Olaparib reduced cell viability at increasing concentrations and SAHA enhanced these effects in 4 of 5 cell lines, including BRCA1 null and wild-type cells, in vitro and in SKOV-3 xenografts in vivo. CONCLUSIONS: These results provide preclinical rationale for targeting DNA damage response pathways by combining small molecule PARPi with HDACi as a mechanism for reducing HR efficiency in ovarian cancer.
OBJECTIVES: Approximately 50% of serous epithelial ovarian cancers (EOC) contain molecular defects in homologous recombination (HR) DNA repair pathways. Poly(ADP-ribose) polymerase inhibitors (PARPi) have efficacy in HR-deficient, but not in HR-proficient, EOC tumors as a single agent. Our goal was to determine whether the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), can sensitize HR-proficient ovarian cancer cells to the PARPi AZD-2281 (olaparib). METHODS:Ovarian cancer cell lines (SKOV-3, OVCAR-8, NCI/ADR-Res, UWB1.289 BRCA1null and UWB1.289+BRCA1 wild-type) were treated with saline vehicle, olaparib, SAHA or olaparib/SAHA. Sulforhodamine B (SRB) assessed cytotoxicity and immunofluorescence and Western blot assays assessed markers of apoptosis (cleaved PARP) and DNA damage (pH2AX and RAD51). Drug effects were also tested in SKOV-3 xenografts in Nude mice. Affymetrix microarray experiments were performed in vehicle and SAHA-treated SKOV-3 cells. RESULTS: In a microarray analysis, SAHA induced coordinated down-regulation of HR pathway genes, including RAD51 and BRCA1. Nuclear co-expression of RAD51 and pH2AX, a marker of efficient HR repair, was reduced approximately 40% by SAHA treatment alone and combined with olaparib. SAHA combined with olaparib induced apoptosis and pH2AX expression to a greater extent than either drug alone. Olaparib reduced cell viability at increasing concentrations and SAHA enhanced these effects in 4 of 5 cell lines, including BRCA1 null and wild-type cells, in vitro and in SKOV-3 xenografts in vivo. CONCLUSIONS: These results provide preclinical rationale for targeting DNA damage response pathways by combining small molecule PARPi with HDACi as a mechanism for reducing HR efficiency in ovarian cancer.
Authors: Xufeng Chen; Patty Wong; Eric H Radany; Jeremy M Stark; Corentin Laulier; Jeffrey Y C Wong Journal: Mol Cancer Res Date: 2012-06-22 Impact factor: 5.852
Authors: Stan B Kaye; Jan Lubinski; Ursula Matulonis; Joo Ern Ang; Charlie Gourley; Beth Y Karlan; Amit Amnon; Katherine M Bell-McGuinn; Lee-May Chen; Michael Friedlander; Tamar Safra; Ignace Vergote; Mark Wickens; Elizabeth S Lowe; James Carmichael; Bella Kaufman Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: Bhupinder S Mann; John R Johnson; Kun He; Rajeshwari Sridhara; Sophia Abraham; Brian P Booth; Leigh Verbois; David E Morse; Josephine M Jee; Sarah Pope; Ravi S Harapanhalli; Ramzi Dagher; Ann Farrell; Robert Justice; Richard Pazdur Journal: Clin Cancer Res Date: 2007-04-15 Impact factor: 12.531
Authors: Brendon Ladd; Jeffrey J Ackroyd; J Kevin Hicks; Christine E Canman; Sheryl A Flanagan; Donna S Shewach Journal: DNA Repair (Amst) Date: 2013-11-11
Authors: Andrew J Wilson; Do-Sun Byun; Shannon Nasser; Lucas B Murray; Kanyalakshmi Ayyanar; Diego Arango; Maria Figueroa; Ari Melnick; Gary D Kao; Leonard H Augenlicht; John M Mariadason Journal: Mol Biol Cell Date: 2008-07-16 Impact factor: 4.138
Authors: Yulia V Surovtseva; Vikram Jairam; Ahmed F Salem; Ranjini K Sundaram; Ranjit S Bindra; Seth B Herzon Journal: J Am Chem Soc Date: 2016-03-09 Impact factor: 15.419
Authors: Panagiotis A Konstantinopoulos; Raphael Ceccaldi; Geoffrey I Shapiro; Alan D D'Andrea Journal: Cancer Discov Date: 2015-10-13 Impact factor: 39.397
Authors: Anne Monks; Yingdong Zhao; Curtis Hose; Hossein Hamed; Julia Krushkal; Jianwen Fang; Dmitriy Sonkin; Alida Palmisano; Eric C Polley; Laura K Fogli; Mariam M Konaté; Sarah B Miller; Melanie A Simpson; Andrea Regier Voth; Ming-Chung Li; Erik Harris; Xiaolin Wu; John W Connelly; Annamaria Rapisarda; Beverly A Teicher; Richard Simon; James H Doroshow Journal: Cancer Res Date: 2018-10-24 Impact factor: 12.701